Table 1.
Baseline demographics comparing unplanned versus planned pregnancies.
| Unplanned | Planned | p value | |
|---|---|---|---|
| N | 20 | 43 | |
| Married (n, (%)) | 12 (60) | 42 (98) | <0.001 |
| Pre-pregnancy body mass index (mean (sd)) | 26.74 (9.12) | 25.80 (5.83) | 0.63 |
| Age at MS diagnosis (mean (sd)) | 25.32 (4.96) | 27.41 (5.07) | 0.13 |
| Age at delivery (mean (sd)) | 29.48 (5.55) | 33.04 (4.33) | 0.007 |
| Number of women who had at least one relapse in the pre-pregnancy year (n (%)) | 6 (30) | 17 (40) | 0.472 |
| Average ARR pre-pregnancy year (mean (sd)) | 0.55 (0.83) | 0.63 (0.98) | 0.759 |
| Number of women who had at least one relapse within the first post-partum year (n (%)) | 12 (60) | 21 (49) | 0.417 |
| Average ARR post-partum year (mean (sd)) | 0.60 (0.68) | 0.65 (0.90) | 0.822 |
| Duration of maternal MS at delivery (mean (sd)) | 4.16 (3.53) | 5.63 (3.64) | 0.139 |
| Assisted reproductive therapy (n (%)) | 0.0 (0.0) | 5 (12) | 0.116 |
| In vitro fertilization (n (%)) | 0 (0.0) | 2 (5.0) | 0.335 |
| On DMT during pregnancy (n (%)) | 13 (65) | 3 (7) | <0.001 |
| DMT (n (%)) | <0.001 | ||
| None | 7 (35.0) | 40 (93.0) | |
| Interferon beta-1a intramuscular | 5 (25.0) | 0 ( 0.0) | |
| Interferon beta-1a subcutaneous | 1 ( 5.0) | 0 ( 0.0) | |
| Interferon beta-1b subcutaneous | 0 ( 0.0) | 1 ( 2.3) | |
| Glatiramer acetate | 3 (15.0) | 2 ( 4.7) | |
| Azathioprine | 1 ( 5.0) | 0 ( 0.0) | |
| Dimethyl fumarate | 1 ( 5.0) | 0 ( 0.0) | |
| Natalizumab | 2 (10.0) | 0 ( 0.0) | |
| Caesarean section (n (%)) | 5 (25) | 19 (44) | 0.149 |
| Birth weight (mean (sd)) | 3.31 (0.51) | 3.13 (0.55) | 0.244 |
| Gestational age (mean (sd)) | 38.75 (1.21) | 38.52 (1.69) | 0.59 |
| Age of menarche (mean (sd)) | 12.78 (1.64) | 12.04 (1.24) | 0.17 |
| Gravida (mean (sd)) | 1.95 (1.15) | 1.77 (1.07) | 0.539 |
| Breast feed (n (%)) | 7 (35) | 27 (63) | 0.04 |
| Duration of breastfeeding in days (mean (sd)) | 44 (87) | 100 (128) | 0.079 |
| Time to restart DMT in days after delivery (mean (sd)) | 392 (684) | 389 (525) | 0.984 |
| Smoking (n (%)) | 6 (30) | 5 (12) | 0.076 |
| Race (n (%)) | 0.792 | ||
| Black | 1 (5.0) | 4 (9.3) | |
| Hispanic | 1 (5.0) | 3 (7.0) | |
| White | 18 (90.0) | 36 (83.7) | |
| EDSS pre-pregnancy (median [IQR]) | 2.25 [1.00, 2.50] | 2 [0.50, 2.50] | 0.319 |
| Post-partum EDSS (median [IQR]) | 2 [1.38, 3.00] | 2 [1.50, 2.50] | 0.712 |
| Change in EDSS (mean (sd)) | 0.07 (0.86) | 0.31 (0.89) | 0.319 |
| New T2 lesions on post-partum MRI (mean (sd)) | 1.20 (1.74) | 2.05 (1.78) | 0.082 |
| Enhancing lesions (mean (sd)) | 0.30 (0.80) | 1.10 (1.54) | 0.034 |
| New T2 lesions prior to conception (mean (sd)) | 0.89 (1.45) | 1.45 (1.70) | 0.22 |
| Enhancing lesions pre-pregnancy (mean (sd)) | 0.68 (1.38) | 0.43 (1.06) | 0.431 |
ARR: annualized relapse rate; DMT: disease modifying therapies; EDSS: Expanded Disability Status Scale; IQR: interquartile range; MRI: magnetic resonance imaging; MS: multiple sclerosis.